Glycemic variability (GV), defined as an integral component of glucose homoeostasis, is
emerging as an important metric to consider when assessing glycemic control in clinical …

Diabetes mellitus is the major risk factor for the development of macrovascular and
microvascular complications. It is increasingly recognized that glycemic variability (GV) …

Glycated hemoglobin A 1c (A1C) levels have traditionally been the gold standard for
assessing glycemic control and treatment efficacy in patients with type 2 diabetes. However …

Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …

Pioglitazone, the only thiazolidinedione drug in clinical practice is under scrutiny due to
reported adverse effects, it's unique insulin sensitising action provides rationale to remain as …

Glycemic variability (GV) appears today as an integral component of glucose homeostasis
for the management of type 2 diabetes (T2D). This review aims at investigating the use and …

Glycemic variability (GV) has been an emerging target for preventing complications related
to type 2 diabetes. For reducing GV, DPP-IV inhibitors have shown effectiveness compared …

Background Glycemic variability (GV) confers a risk of cardiovascular events. In this study,
we aimed to investigate whether long-term GV has an impact on coronary atherosclerosis …

Background To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability
on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM) …

Background Glycemic variability is associated with the development of diabetic
complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 …